Shares of CRBP opened at $8.78 on Friday. The firm has a market cap of $106.94 million, a PE ratio of -1.87 and a beta of 2.63. Corbus Pharmaceuticals has a 12 month low of $8.74 and a 12 month ...

Shares of CRBP stock opened at $9.78 on Monday. The company’s fifty day simple moving average is $12.65 and its two-hundred day simple moving average is $27.00. Corbus Pharmaceuticals has a 52 ...

In a report released on February 7, Andrew Fein from H.C. Wainwright maintained a Buy rating on Corbus Pharmaceuticals (CRBP – Research Report), with a price target of $75.00. The company’s ...

Corbus Pharmaceuticals (CRBP) announced that the abstract for its first-in-human dose escalation clinical study conducted in the United States and Europe of CRB-701 has been released. The ...

(RTTNews) - Corbus Pharmaceuticals Holdings, Inc. (CRBP) announced on Tuesday that it will present updated data from its Phase 1 dose escalation study of CRB-701 or SYS6002 at the 2025 American ...

This feature is currently unavailable; we are sorry for the inconvenience to you. Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Insider trading activity involves company insiders, such as executives, directors, and employees, engaging in transactions of their own company's stock. Insiders' buy and sell transactions provide ...